About Cergentis
Cergentis is a company based in Utrecht (Netherlands) founded in 2012 was acquired by Solvias in July 2022.. Cergentis offers products and services including Targeted Locus Amplification (TLA). Cergentis operates in a competitive market with competitors including RareCyte, Sequenta, seqWell, Paragon Genomics and Neogen, among others.
- Headquarter Utrecht, Netherlands
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Jurisdiction Bangalore North, Karnataka, India
-
Annual Revenue
$403.09 K (USD)19.31as on Mar 31, 2022
-
Net Profit
$26.11 K (USD)-14.87as on Mar 31, 2022
-
EBITDA
$31.2 K (USD)28.43as on Mar 31, 2022
-
Latest Funding Round
$1.41 M (USD), Grant
Apr 30, 2020
-
Investors
Solvias
& 2 more
-
Employee Count
Employee Count
-
Acquired by
Solvias
(Jul 12, 2022)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Cergentis
Cergentis offers a comprehensive portfolio of products and services, including Targeted Locus Amplification (TLA). The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Platform for genetic characterization and QC in advanced therapies.
Unlock access to complete
Unlock access to complete
Funding Insights of Cergentis
- Total Funding Total Funding
- Total Rounds 2
- Last Round Grant — $1.4M
-
First Round
First Round
(01 May 2018)
- Investors Count 2
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Apr, 2020 | Amount | Grant - Cergentis | Valuation |
investors |
|
| May, 2018 | Amount | Grant - Cergentis | Valuation |
investors |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Cergentis
Cergentis has secured backing from 3 investors, including venture fund and institutional investors. Prominent investors backing the company include Solvias, European Union and EIC Fund. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Government agency and accelerator focusing on innovative startups and SMEs
|
Founded Year | Domain | Location | |
|
Government entites focused on freedom, democracy, equality and the rule of law, promoting peace and stability
|
Founded Year | Domain | Location | |
|
Integrated R&D services are provided for pharmaceuticals and allied sectors.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Cergentis
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Cergentis
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Cergentis Comparisons
Competitors of Cergentis
Cergentis operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as RareCyte, Sequenta, seqWell, Paragon Genomics and Neogen, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Developer of technologies for the analysis of rare and single cells in the blood
|
|
| domain | founded_year | HQ Location |
Immuno-sequencing products are developed for disease diagnostics and treatment.
|
|
| domain | founded_year | HQ Location |
NGS-based reagents and kits are supplied for life sciences research.
|
|
| domain | founded_year | HQ Location |
Provider of technologies and solutions genomic research and precision medicine
|
|
| domain | founded_year | HQ Location |
Manufacturer of products in the areas of veterinary diagnostics, life sciences, DNA testing, and drug testing
|
|
| domain | founded_year | HQ Location |
Molecular biology reagents and services are supplied to biotech industries.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Frequently Asked Questions about Cergentis
When was Cergentis founded?
Cergentis was founded in 2012 and raised its 1st funding round 6 years after it was founded.
Where is Cergentis located?
Cergentis is headquartered in Utrecht, Netherlands.
What is the annual revenue of Cergentis?
Annual revenue of Cergentis is $403.09K as on Mar 31, 2022.
What does Cergentis do?
Cergentis was founded in 2012 and is based in Utrecht, Netherlands. Targeted sequencing kits and services are offered in the genomics sector. The proprietary Targeted Locus Amplification (TLA) technology is employed to achieve complete next-generation sequencing of genomic loci through a single primer pair, amplifying thousands of base pairs. Applications encompass oncogenetics, transgene integration site analysis, full gene sequencing, genetic diagnostics, and agricultural genomics.
Who are the top competitors of Cergentis?
Cergentis's top competitors include Neogen, Paragon Genomics and Biotangents.
What products or services does Cergentis offer?
Cergentis offers Targeted Locus Amplification (TLA).
Who are Cergentis's investors?
Cergentis has 3 investors. Key investors include Solvias, European Union, and EIC Fund.